Winson Holdings Hong Kong Limited

Income statement

Notes to 6.1:

• FY2022 and FY2023 cost of services is computed as revenue minus gross profit.

• Pre-tax income is derived from the S&P pre-tax margin. The FY2024 figure (HK$13.3M) matches the profit warning's comparative. For FY2025, the profit warning's unaudited estimate was a pre-tax loss of about HK$12.0M. The derived audited figure (about HK$10.3M) is not confirmed in the sections reviewed; treat it as approximate.

• EPS is computed as attributable profit divided by 600.0M shares. Diluted EPS is assumed equal to basic because the outstanding options are immaterial (168,000 pre-IPO options as at the 2020 transfer).

• FY2024 DPS is shown as 0.7 HK cents (S&P). The company reported a 40.0% payout ratio, which implies about 0.66 to 0.73 cents depending on the base used.

• FY2025 had no dividend.

• The FY2026 final dividend of HK0.8 cent (total HK$4.8M) was recommended on 23 June 2026.

Margins (%)

Revenue CAGR:

• FY2022 to FY2026 (four years): about +2.1% per year (473.7 to 515.5).

• FY2021 to FY2026 (five years, from the COVID-boosted HK$530.0M base): about -0.6% per year.

Both CAGRs are computed. FY2021 revenue of HK$530.0M and profit of HK$73.8M are from AR FY2022 highlights.

Balance sheet

Notes to 6.3:

• FY2022 to FY2024 total assets and current items are from ET Net (current plus non-current assets). FY2024 total assets of 282.0 agree with AR FY2025.

• Cash is company-reported. S&P "cash and investments" shows 117.66, 154.37, 94.20, 102.10 and 79.05.

• Total debt is from S&P and consists mostly of lease liabilities plus a small bank loan. The short/long-term split is not disclosed in the sections reviewed.

• The company gearing ratio (lease liabilities and bank borrowings divided by equity) was 0.01 (FY2024), 0.005 (FY2025) and 0.002 (FY2026).

• Leasehold land and buildings with a carrying value of HK$21.2M (FY2026) are pledged for banking facilities.

Cash flow

Notes to 6.4:

• Capex conflicts between S&P and company PPE purchases in FY2024 (27.2 vs 31.1) and FY2026 (1.4 vs 2.9). The company figure includes the HK$21.4M head-office purchase completed in FY2024.

• Dividends paid are not disclosed in the sections reviewed. Declared totals imply about HK$4M paid in FY2025, relating to the FY2024 dividend, and nil in FY2026.

• No share repurchases are recorded in the sections reviewed.

• The Lask JV consideration (about HK$19.8M) is an investing outflow in FY2025 and is not included in capex.

Key ratios

Notes to 6.5:

• FY2024 to FY2026 ROE, ROA, current ratio, gearing and interest coverage are company-reported (AR FY2025, AR FY2026).

• FY2022 and FY2023 values are computed.

• Net debt to EBITDA is not meaningful because the company holds net cash.

Commentary on trends, inflections and drivers

Revenue.

• Revenue has been essentially flat in a HK$460–480M band from FY2022 to FY2025, after the FY2021 COVID-hygiene peak of HK$530M.

• FY2026 broke out of the band (+7.7% to HK$515.5M). The driver was public healthcare contracts that began contributing in November 2025, so the full-year effect will land in FY2027.

• Offsetting this, contracts on hand fell from HK$685M to HK$525M during FY2026. Renewal values fell from HK$195M to HK$127M as aggressive competitor pricing cost the Group some high-value contracts and customers cut service scope.

• The order book therefore points to a healthy new-business pipeline but a thinner renewal base.

Gross margin.

• The structural inflection came in FY2025, when the gross margin fell from 14.1% to 8.9% (down 5.2 percentage points). That year staff costs rose 11.1% (to HK$324.2M) on revenue growth of only 1.7%.

• Management attributed the decline to:

  • labour shortage and wage inflation;

  • "all-inclusive" scope creep;

  • human-resource obligations embedded in a renewed railway contract.

• FY2026 stabilised the margin at 9.0%; EHS alone improved to 9.8%. The Group-level gain was diluted by the PMS start-up loss.

• Staff costs now absorb 70.3% of revenue.

Operating line.

• General operating expenses have been sticky at about HK$56M.

• At a 9% gross margin, the Group needs roughly HK$620M of revenue at constant overhead to break even at the operating level. This is a computed, illustrative figure.

• Losses in FY2025 and FY2026 are therefore structural rather than one-off. The FY2026 loss narrowed partly because of a HK$1.8M share of associate profit and finance income.

Balance sheet.

• The balance sheet is very strong relative to the business: net cash of HK$76.9M, debt of HK$0.4M, current ratio of 2.6x.

• However, cash has fallen from HK$154.0M (FY2023) to HK$77.3M (FY2026). The decline reflects:

  • the head-office property purchase (about HK$21.4M, FY2024);

  • the Lask JV investment (about HK$19.8M, FY2025);

  • working-capital absorption in FY2024 and FY2026, when operating cash flow was negative;

  • dividends.

• The negative FY2026 operating cash flow (-HK$18.1M) is consistent with receivables building on newly started healthcare contracts.

Capital returns.

• The FY2026 dividend (HK$4.8M) was declared despite a HK$5.3M loss and negative free cash flow, so it is funded from balance-sheet cash.

Management guidance (AR FY2026, qualitative).

• Revenue growth momentum is expected to pick up steadily in the latter part of 2026 and beyond.

• Drivers cited:

  • EHS contracts on hand;

  • the Chengdu project, which should generate new PRC income and ease the cost burden borne during two years of preparation;

  • expansion into other public service segments and private healthcare and wellness;

  • accelerated Greater Bay Area development with the associate.

• No numerical targets are provided.

Consensus: none; there is no analyst coverage.

Bull case:

1. Operating leverage from a full healthcare year. Healthcare revenue began in November 2025. A full twelve months, plus FY2026's record HK$265.1M of new contracts, could lift revenue towards the HK$560–620M range. At a 9–10% gross margin and flat overhead of about HK$56M, that would bring the Group back to around operating breakeven or profit. This is an illustrative computation, not guidance.

2. Chengdu ramps into a margin-accretive fee stream. FY2026's HK$3.6M PMS gross loss reflects start-up costs. As occupancy and footfall build, the losses should reverse and the PRC becomes a second growth engine.

3. Balance-sheet optionality at below book value. At about 0.79x P/B and an EV of about 0.15x sales, with HK$77M of net cash and an owned head office, downside is cushioned and the dividend has resumed.

Bear case:

1. Renewal erosion outweighs new wins. The order book fell 23% to HK$525M and renewal value fell 35% to HK$127M. Competitors such as HK Johnson are bidding at about 3% gross margins, so Winson may have to choose between volume and margin.

2. Structural cost squeeze. Staff costs are already 70% of revenue. Further minimum-wage increases or tighter human-resource terms on large transit and healthcare contracts could keep EHS margins near 9% and the Group loss-making.

3. Related-party PRC expansion consumes cash. Cash has halved since FY2023 to HK$77.3M, and operating cash flow was negative in FY2026. The Lask JV (connected vendor, profit-guarantee shortfall indicators) and further Greater Bay Area deals with family-linked entities could divert capital with limited minority-shareholder protection.

Key catalysts and monitorables (next 12 months):

• Interims for the six months to 30 September 2026 (expected around 24 November 2026). Watch:

  • EHS revenue run-rate with full healthcare contribution;

  • gross margin versus 9.8%;

  • general operating expenses;

  • operating cash flow and receivables;

  • PMS losses.

• Order-book updates: contracts on hand versus HK$525M; renewal rate; new tender wins in transit and healthcare.

• Chengdu occupancy and phase openings; any disclosure of PMS revenue scale.

• Lask JV: share of results; profit-guarantee settlement for the final guarantee year; any new connected transactions in the Greater Bay Area.

• Labour policy: minimum-wage review outcomes and changes to the imported-labour scheme.

• Capital allocation: sustainability of the dividend given negative free cash flow; any buybacks under the general mandate.

• Governance: the planned FY2027 board evaluation; succession for independent directors approaching nine years' tenure; possible CEO appointment.

Concluding analyst verdict.

Winson is a cash-rich, family-controlled Hong Kong cleaning contractor emerging from a sharp margin reset. FY2025 showed how exposed the model is to labour costs: a 5.2-point gross-margin collapse turned a HK$10.9M profit into a HK$10.9M loss on almost unchanged revenue.

FY2026 offers genuine but incomplete evidence of repair:

• revenue grew 7.7%, the best growth in five years;

• EHS gross margin recovered to 9.8%;

• tender success and renewal rates rebounded strongly;

• new contract value nearly tripled on the back of a defensible healthcare niche.

Two counterweights temper this. First, the order book is shrinking because renewals are being repriced or lost. Second, overhead of about HK$56M still exceeds gross profit.

The equity story therefore depends on whether FY2027 converts a full year of healthcare revenue and the Chengdu ramp into operating breakeven. On our illustrative arithmetic, that needs revenue of roughly HK$600M or more, or a gross margin above 10%.

The PRC strategy is the central judgement call. Strategically, it moves Winson from a capped, price-competitive Hong Kong labour market into larger property-operations pools. In execution and governance terms, it relies on connected parties and an untested Chengdu mandate, and so far it has diluted margins.

Valuation offers support. The stock trades at about 0.8x book and an EV of about HK$76M, roughly 0.15x sales, with negligible debt and an owned head office. The resumed dividend yields about 3%. Liquidity is thin and there is no research coverage, which limits re-rating catalysts to the company's own disclosures.

Overall assessment: a speculative, balance-sheet-supported recovery situation. The upside depends on evidence of operating leverage in the November 2026 interim. The main risks are continued renewal erosion, cash drain from PRC expansion and related-party capital allocation. Investors should treat the November 2026 interims as the decisive checkpoint, focusing on EHS margin, operating cash flow and PMS loss trajectory, before underwriting a sustained turnaround.